Epithelial-mesenchymal transition predicts polo-like kinase 1 inhibitor-mediated apoptosis in non-small cell lung cancer

Renata Ferrarotto, Ruchitha Goonatilake, Suk Young Yoo, Pan Tong, Uma Giri, Shaohua Peng, John Minna, Luc Girard, Yuehong Wang, Liguang Wang, Lerong Li, Lixia Diao, David H. Peng, Don L. Gibbons, Bonnie S. Glisson, John V. Heymach, Jing Wang, Lauren A. Byers, Faye M. Johnson

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Purpose: To identify new therapeutic targets for non-small cell lung cancer (NSCLC), we systematically searched two cancer cell line databases for sensitivity data on a broad range of drugs. We identified polo-like kinase 1 (PLK1) as the most promising target for further investigation based on a subset of sensitive NSCLC cell lines and inhibitors that were in advanced clinical development. Experimental Design: To identify potential biomarkers of response of NSCLC to PLK1 inhibition and mechanisms of PLK1 inhibitor-induced apoptosis, integrated analysis of gene and protein expression, gene mutations, and drug sensitivity was performed using three PLK1 inhibitors (volasertib, BI2536, and GSK461364) with a large panel of NSCLC cell lines. Results: The NSCLC cell lines had different sensitivities to PLK1 inhibition, with a minority demonstrating sensitivity to all three inhibitors. PLK1 inhibition led to G2-M arrest, but only treatment-sensitive cell lines underwent substantial apoptosis following PLK1 inhibition. NSCLC lines with high epithelial-mesenchymal transition (EMT) gene signature scores (mesenchymal cell lines) were more sensitive to PLK1 inhibition than epithelial lines (P <0.02). Likewise, proteomic profiling demonstrated that E-cadherin expression was higher in the resistant cell lines than in the sensitive ones (P <0.01). Induction of an epithelial phenotype by expression of the miRNA miR-200 increased cellular resistance to PLK1 inhibition. Also, KRAS mutation and alterations in the tight-junction, ErbB, and Rho signaling pathways correlated with drug response of NSCLC. Conclusions: In this first reported large-scale integrated analysis of PLK1 inhibitor sensitivity, we demonstrated that EMT leads to PLK1 inhibition sensitivity of NSCLC cells. Our findings have important clinical implications for mesenchymal NSCLC, a significant subtype of the disease that is associated with resistance to currently approved targeted therapies. Clin Cancer Res; 22(7); 1674-86.

Original languageEnglish (US)
Pages (from-to)1674-1686
Number of pages13
JournalClinical Cancer Research
Volume22
Issue number7
DOIs
StatePublished - Apr 1 2016

Fingerprint

Epithelial-Mesenchymal Transition
Non-Small Cell Lung Carcinoma
Apoptosis
Cell Line
polo-like kinase 1
Pharmaceutical Preparations
Mutation
Tight Junctions
Cadherins
MicroRNAs
Proteomics
Genes
Neoplasms
Research Design
Biomarkers
Databases
Phenotype

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Epithelial-mesenchymal transition predicts polo-like kinase 1 inhibitor-mediated apoptosis in non-small cell lung cancer. / Ferrarotto, Renata; Goonatilake, Ruchitha; Yoo, Suk Young; Tong, Pan; Giri, Uma; Peng, Shaohua; Minna, John; Girard, Luc; Wang, Yuehong; Wang, Liguang; Li, Lerong; Diao, Lixia; Peng, David H.; Gibbons, Don L.; Glisson, Bonnie S.; Heymach, John V.; Wang, Jing; Byers, Lauren A.; Johnson, Faye M.

In: Clinical Cancer Research, Vol. 22, No. 7, 01.04.2016, p. 1674-1686.

Research output: Contribution to journalArticle

Ferrarotto, R, Goonatilake, R, Yoo, SY, Tong, P, Giri, U, Peng, S, Minna, J, Girard, L, Wang, Y, Wang, L, Li, L, Diao, L, Peng, DH, Gibbons, DL, Glisson, BS, Heymach, JV, Wang, J, Byers, LA & Johnson, FM 2016, 'Epithelial-mesenchymal transition predicts polo-like kinase 1 inhibitor-mediated apoptosis in non-small cell lung cancer', Clinical Cancer Research, vol. 22, no. 7, pp. 1674-1686. https://doi.org/10.1158/1078-0432.CCR-14-2890
Ferrarotto, Renata ; Goonatilake, Ruchitha ; Yoo, Suk Young ; Tong, Pan ; Giri, Uma ; Peng, Shaohua ; Minna, John ; Girard, Luc ; Wang, Yuehong ; Wang, Liguang ; Li, Lerong ; Diao, Lixia ; Peng, David H. ; Gibbons, Don L. ; Glisson, Bonnie S. ; Heymach, John V. ; Wang, Jing ; Byers, Lauren A. ; Johnson, Faye M. / Epithelial-mesenchymal transition predicts polo-like kinase 1 inhibitor-mediated apoptosis in non-small cell lung cancer. In: Clinical Cancer Research. 2016 ; Vol. 22, No. 7. pp. 1674-1686.
@article{6b403d15b17e4318ad0eeac8d45aa6a8,
title = "Epithelial-mesenchymal transition predicts polo-like kinase 1 inhibitor-mediated apoptosis in non-small cell lung cancer",
abstract = "Purpose: To identify new therapeutic targets for non-small cell lung cancer (NSCLC), we systematically searched two cancer cell line databases for sensitivity data on a broad range of drugs. We identified polo-like kinase 1 (PLK1) as the most promising target for further investigation based on a subset of sensitive NSCLC cell lines and inhibitors that were in advanced clinical development. Experimental Design: To identify potential biomarkers of response of NSCLC to PLK1 inhibition and mechanisms of PLK1 inhibitor-induced apoptosis, integrated analysis of gene and protein expression, gene mutations, and drug sensitivity was performed using three PLK1 inhibitors (volasertib, BI2536, and GSK461364) with a large panel of NSCLC cell lines. Results: The NSCLC cell lines had different sensitivities to PLK1 inhibition, with a minority demonstrating sensitivity to all three inhibitors. PLK1 inhibition led to G2-M arrest, but only treatment-sensitive cell lines underwent substantial apoptosis following PLK1 inhibition. NSCLC lines with high epithelial-mesenchymal transition (EMT) gene signature scores (mesenchymal cell lines) were more sensitive to PLK1 inhibition than epithelial lines (P <0.02). Likewise, proteomic profiling demonstrated that E-cadherin expression was higher in the resistant cell lines than in the sensitive ones (P <0.01). Induction of an epithelial phenotype by expression of the miRNA miR-200 increased cellular resistance to PLK1 inhibition. Also, KRAS mutation and alterations in the tight-junction, ErbB, and Rho signaling pathways correlated with drug response of NSCLC. Conclusions: In this first reported large-scale integrated analysis of PLK1 inhibitor sensitivity, we demonstrated that EMT leads to PLK1 inhibition sensitivity of NSCLC cells. Our findings have important clinical implications for mesenchymal NSCLC, a significant subtype of the disease that is associated with resistance to currently approved targeted therapies. Clin Cancer Res; 22(7); 1674-86.",
author = "Renata Ferrarotto and Ruchitha Goonatilake and Yoo, {Suk Young} and Pan Tong and Uma Giri and Shaohua Peng and John Minna and Luc Girard and Yuehong Wang and Liguang Wang and Lerong Li and Lixia Diao and Peng, {David H.} and Gibbons, {Don L.} and Glisson, {Bonnie S.} and Heymach, {John V.} and Jing Wang and Byers, {Lauren A.} and Johnson, {Faye M.}",
year = "2016",
month = "4",
day = "1",
doi = "10.1158/1078-0432.CCR-14-2890",
language = "English (US)",
volume = "22",
pages = "1674--1686",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Epithelial-mesenchymal transition predicts polo-like kinase 1 inhibitor-mediated apoptosis in non-small cell lung cancer

AU - Ferrarotto, Renata

AU - Goonatilake, Ruchitha

AU - Yoo, Suk Young

AU - Tong, Pan

AU - Giri, Uma

AU - Peng, Shaohua

AU - Minna, John

AU - Girard, Luc

AU - Wang, Yuehong

AU - Wang, Liguang

AU - Li, Lerong

AU - Diao, Lixia

AU - Peng, David H.

AU - Gibbons, Don L.

AU - Glisson, Bonnie S.

AU - Heymach, John V.

AU - Wang, Jing

AU - Byers, Lauren A.

AU - Johnson, Faye M.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Purpose: To identify new therapeutic targets for non-small cell lung cancer (NSCLC), we systematically searched two cancer cell line databases for sensitivity data on a broad range of drugs. We identified polo-like kinase 1 (PLK1) as the most promising target for further investigation based on a subset of sensitive NSCLC cell lines and inhibitors that were in advanced clinical development. Experimental Design: To identify potential biomarkers of response of NSCLC to PLK1 inhibition and mechanisms of PLK1 inhibitor-induced apoptosis, integrated analysis of gene and protein expression, gene mutations, and drug sensitivity was performed using three PLK1 inhibitors (volasertib, BI2536, and GSK461364) with a large panel of NSCLC cell lines. Results: The NSCLC cell lines had different sensitivities to PLK1 inhibition, with a minority demonstrating sensitivity to all three inhibitors. PLK1 inhibition led to G2-M arrest, but only treatment-sensitive cell lines underwent substantial apoptosis following PLK1 inhibition. NSCLC lines with high epithelial-mesenchymal transition (EMT) gene signature scores (mesenchymal cell lines) were more sensitive to PLK1 inhibition than epithelial lines (P <0.02). Likewise, proteomic profiling demonstrated that E-cadherin expression was higher in the resistant cell lines than in the sensitive ones (P <0.01). Induction of an epithelial phenotype by expression of the miRNA miR-200 increased cellular resistance to PLK1 inhibition. Also, KRAS mutation and alterations in the tight-junction, ErbB, and Rho signaling pathways correlated with drug response of NSCLC. Conclusions: In this first reported large-scale integrated analysis of PLK1 inhibitor sensitivity, we demonstrated that EMT leads to PLK1 inhibition sensitivity of NSCLC cells. Our findings have important clinical implications for mesenchymal NSCLC, a significant subtype of the disease that is associated with resistance to currently approved targeted therapies. Clin Cancer Res; 22(7); 1674-86.

AB - Purpose: To identify new therapeutic targets for non-small cell lung cancer (NSCLC), we systematically searched two cancer cell line databases for sensitivity data on a broad range of drugs. We identified polo-like kinase 1 (PLK1) as the most promising target for further investigation based on a subset of sensitive NSCLC cell lines and inhibitors that were in advanced clinical development. Experimental Design: To identify potential biomarkers of response of NSCLC to PLK1 inhibition and mechanisms of PLK1 inhibitor-induced apoptosis, integrated analysis of gene and protein expression, gene mutations, and drug sensitivity was performed using three PLK1 inhibitors (volasertib, BI2536, and GSK461364) with a large panel of NSCLC cell lines. Results: The NSCLC cell lines had different sensitivities to PLK1 inhibition, with a minority demonstrating sensitivity to all three inhibitors. PLK1 inhibition led to G2-M arrest, but only treatment-sensitive cell lines underwent substantial apoptosis following PLK1 inhibition. NSCLC lines with high epithelial-mesenchymal transition (EMT) gene signature scores (mesenchymal cell lines) were more sensitive to PLK1 inhibition than epithelial lines (P <0.02). Likewise, proteomic profiling demonstrated that E-cadherin expression was higher in the resistant cell lines than in the sensitive ones (P <0.01). Induction of an epithelial phenotype by expression of the miRNA miR-200 increased cellular resistance to PLK1 inhibition. Also, KRAS mutation and alterations in the tight-junction, ErbB, and Rho signaling pathways correlated with drug response of NSCLC. Conclusions: In this first reported large-scale integrated analysis of PLK1 inhibitor sensitivity, we demonstrated that EMT leads to PLK1 inhibition sensitivity of NSCLC cells. Our findings have important clinical implications for mesenchymal NSCLC, a significant subtype of the disease that is associated with resistance to currently approved targeted therapies. Clin Cancer Res; 22(7); 1674-86.

UR - http://www.scopus.com/inward/record.url?scp=84964343747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964343747&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-14-2890

DO - 10.1158/1078-0432.CCR-14-2890

M3 - Article

C2 - 26597303

AN - SCOPUS:84964343747

VL - 22

SP - 1674

EP - 1686

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 7

ER -